Technology has potential to reimagine treatment for amblyopia (“lazy eye”), a leading cause of vision loss in children and young adults1Acquisition expands the Novartis refractive disorder pipeline in ophthalmologyNovartis will work with Ubisoft and Mc…
Novartis is teaming up with R&D leaders throughout the industry as part of the National Institutes of Health (NIH) and the Foundation for NIH (FNIH) Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) partnership initiative. Collab…
Real-world evidence supports benefits seen in Aimovig clinical trials Open-label data highlight long-term efficacy and safety profile of Aimovig in episodic and chronic migraine Post-hoc and real-world data show preventive treatment with Aimovig signi…
We are grateful to all patient organizations who have provided feedback on our work and take the opportunity to thank them for the hard work they are doing to support patients around the world, particularly in these challenging times of the COVID-19 cr…
Basel, April 8, 2020 — Patient safety is at the heart of everything we do. Whenever adverse events are reported, we take them seriously and investigate them thoroughly.As part of its safety surveillance program, Novartis has been actively evaluating po…
Chagas disease is a major public health challenge. It affects approximately 6 million people1, mainly in Latin America. Less than 1% of affected individuals receive proper treatment2. For the first time, the global community is preparing to celebrate A…
Novartis is making rapid progress in distributing the allocated USD 20 million of the Novartis COVID-19 Response Fund, announced mid-March, to impacted countries around the world. The fund aims to support public health initiatives designed to help comm…
Novartis has committed to making a global donation of up to 130 million doses of the anti-malarial drug hydroxychloroquine to support efforts to fight the COVID-19 pandemic.Sandoz, the generics and biosimilars division of Novartis, today begins deliver…
New clinical trial to evaluate Jakavi® (ruxolitinib) in patients with COVID-19 associated cytokine storm Cytokine storm is a type of severe immune overreaction that can result from coronavirus infection and may contribute to respiratory compromise in …
Basel, April 2, 2020 – Novartis today announced the mutual agreement with Aurobindo Pharma USA Inc. to terminate the agreement to sell the Sandoz US generic oral solids and dermatology businesses to Aurobindo Pharma USA Inc. This decision was taken as …